Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Journal of Medical Economics
|
September 12, 2009
Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective
Louis Bessette, Nancy Risebrough, Nicole Mittmann, et al.
Respiratory Medicine
|
December 5, 2018
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective
Maurice Driessen, Dhvani Shah, Nancy Risebrough, et al.
Cost Effectiveness and Resource Allocation : C/E
|
May 19, 2018
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
Dhvani Shah, Maurice Driessen, Nancy Risebrough, et al.
ERJ Open Research
|
March 29, 2021
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
Elisabeth Fenwick, Alan Martin, Melanie Schroeder, et al.
Respiratory Medicine
|
September 2, 2014
COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada
Afisi S Ismaila, Nancy Risebrough, Chunmei Li, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 14, 2019
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
Victoria Federico Paly, Ian Naya, Necdet B Gunsoy, et al.
ERJ Open Research
|
February 24, 2022
Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
Alan Martin, Dhvani Shah, Kerigo Ndirangu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 16, 2017
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting
Martine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, et al.
Current Oncology (Toronto, Ont.)
|
April 3, 2021
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial
Anca Prica, Annette E Hay, Michael Crump, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 11, 2019
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
Afisi S Ismaila, Nancy Risebrough, Melanie Schroeder, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Journal of Medical Economics
|
September 12, 2009
Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective
Louis Bessette, Nancy Risebrough, Nicole Mittmann, et al.
Respiratory Medicine
|
December 5, 2018
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective
Maurice Driessen, Dhvani Shah, Nancy Risebrough, et al.
Cost Effectiveness and Resource Allocation : C/E
|
May 19, 2018
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
Dhvani Shah, Maurice Driessen, Nancy Risebrough, et al.
ERJ Open Research
|
March 29, 2021
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
Elisabeth Fenwick, Alan Martin, Melanie Schroeder, et al.
Respiratory Medicine
|
September 2, 2014
COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada
Afisi S Ismaila, Nancy Risebrough, Chunmei Li, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 14, 2019
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
Victoria Federico Paly, Ian Naya, Necdet B Gunsoy, et al.
ERJ Open Research
|
February 24, 2022
Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
Alan Martin, Dhvani Shah, Kerigo Ndirangu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 16, 2017
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting
Martine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, et al.
Current Oncology (Toronto, Ont.)
|
April 3, 2021
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial
Anca Prica, Annette E Hay, Michael Crump, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 11, 2019
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
Afisi S Ismaila, Nancy Risebrough, Melanie Schroeder, et al.
Page
of 2